natgillin/translations-raw huggingface dataset:
The compound or a salt thereof as set forth in claim 4, wherein the monocyclic nitrogen-containing hetero ring which may be substituted, formed by Ra and Rb which are combined with the adjacent nitrogen atom, is piperidyl or piperazinyl, each of which may be substituted. 
, R5 i R6 su vodik, Ra i Rb su spojeni sa susjednim atomom dušika da formiraju monociklički hetero prsten s dušikom, koji može biti supstituiran skupinom izabranom od:
The pharmaceutical composition for use according to claim 9, wherein the pharmaceutical composition is prepared for dermal, mucosal, submucosal, transdermal, i.m. i.v., s.c, intradermal, oral, nasal, intraocular or suppository administration or instillation into cavities. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što farmaceutski pripravak se pripravlja za dermalnu, mukoznu, submukoznu, transdermalnu, i.m., i.v., s.c, intradermalnu, oralnu, nazalnu, intraokularnu ili supozitorijsku primjenu ili ukapavanje u šupljine.
The inner part may comprise one or more protrusions extending inwardly in the packaging. 
Unutarnji dio može sadržavati jedno izbočenje ili više izbočenja koja se pružaju prema unutra u pakiranje.
whereby said derivative is a polypeptide molecule which is at least 70% identical in sequence with the original CERT sequence or its complementary sequence or said derivative is a homologous CERT sequence from a different organism and whereby said mutant is based on targeted modification of CERT sequences by substitution, insertion or deletion of one to ten amino acids. 
HR P20121077 TI različitog organizma, te pri čemu je spomenuti mutant baziran na ciljanoj modifikaciji CERT-sekvenci pomoću zamjene, umetanja ili izbacivanja od jedne do deset amino kiselina.
An apparatus of claim 5, wherein said line for oil well tubing heating, by high-frequency currents, further contains at least two inductors placed on oil well tubing and connected to said third cord of the three-cord electrical cable. An apparatus of claim 6, wherein the ultrasonic magnetostrictive radiator has an inside diameter that matches an oil well tubing inside diameter. 
Uredaj prema zahtjevu 5, naznačen time, što spomenuta linija za zagrijavanje cjevovoda naftnog izvora strujama visoke frekvencije dalje sadrži najmanje dva induktora (14, 15) postavljena na cjevovod naftnog izvora (5) i povezana na spomenutu treću žicu (11) trožičnog električnog kabla (9).
A compound according to claim 1, wherein R1 represents a hydrogen atom; and R represents a C2-C5 alkyl, C3-C6 cycloalkyl or tetrahydropyranyl group, or R2 represents a group -NR3R4 in which R3 and R4 each independently represent a C1-C3 alkyl group, or R3 and R4 together with the nitrogen atom to which they are attached form a saturated 4- to 6-membered heterocyclic ring. 
Spoj prema zahtjevu 1, naznačen time da predstavlja vodikov atom; i R predstavlja skupinu C2-C5 alkil, C3-C6 cikloalkil ili tetrahidropiranil, ili predstavlja skupinu -NR3R4 u kojoj R3 i R4 svaki neovisno predstavljaju skupinu C1-C3 alkil, ili R3 i R4 zajedno s dušikovim atomom na koji su oni vezani tvore zasićeni 4- do 6-člani heterociklički prsten.
A first and second aspect of the present invention relates to trisaccharide derivates and their use as an adjuvant. The trisaccharide derivates according to the present invention comprise a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups. 
HR P2071947 TI PATENTNI ZAHTJEVI Upotreba trisaharidnog derivata koji sadrži supstituiranu trisaharidnu jezgru, gdje je navedena trisaharidna jezgra posve supstituirana s esterskim skupinama masnih kiselina, te moguće s jednom ili više anionskih skupina, naznačena time što je trisaharidni derivat namijenjen primjeni kao adjuvans.
A compound according to claim 1, wherein said compound is 4-[3-(3-Fluoro-4-methanesulfonylphenoxy)propyl]-1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidine or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da navedeni spoj je 4-[3-(3-Fluoro-4-metan-sulfonilfenoksi)propil]1-(3-izopropil-[1,2,4]oksadiazol-5-il)piperidin ili njegova farmaceutski prihvatljiva sol.
A process according to claim 4, wherein the solution comprisesat least 1% (V:V) isopropanol. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što otopina sadrži najmanje 1% (vol.:vol) izopropanola.
having a reflection in an X-ray powder diffractogram using CuKa1 radiation at 7.7±0.2 degrees 2theta. 
xHCI (D naznačen time da ima refleksiju u difraktogramu X-zraka na prahu korištenjem CuKa, zračenja kod 7.7 + 0.2 stupnjeva 2theta.
an in vivo method of inhibiting a cancer stem cell to treat cancer in a subject, the method comprising administering to a cancer stem cell an effective amount of the compound; 
liječenju raka u bolesnika za kojeg je ispitano da ima rak koji pokazuje neprirodnu aktivnost signalnog puta Stat3 preko primjene terapijski učinkovite količine spoja formule VIII bolesniku;
The method according to claim 3, characterized in that the metering member (101, 102) is moved in a plane parallel to the metering plate (91, 92). 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se dozirni element (101.102) pomiče u ravnini paralelnoj u odnosu na dozirnu ploču (91,92).
The film as claimed in claim 2 wherein the base layer (301) is devoid of monomeric and/or polymeric plasticisers. 
Film u skladu s patentnim zahtjevom 2, naznačen time, da temeljni sloj (301) ne sadržava monomerne i / ili polimerne plastifikatore.
In addition, these articles did not have a cellulose acetate/polypropylene tube. 
Dalje, ovi proizvodi nisu imali cijev od acetata celuloze/polipropilena.
Pharmaceutical composition according to the present invention is preferably in the form of a tablet or capsule. 
Preferira se da je farmaceutski pripravak prema ovom izumu u obliku tablete ili kapsule.
The method of claim 1 wherein the second administration of pirfenidone further comprises, prior to step (a), administering to said patient pirfenidone at doses lower than 1600 mg/day for about a week, or until biomarkers of liver function are within normal limits. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 1, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 1600 mg/dan u tijeku vremenskog perioda.
The hydrogenation mixture was filtered and the solvent was removed under reduced pressure. 
Hidrogenizirana smjesa se potom filtrira i otapalo se ukloni pri sniženom tlaku.
a monoclonal antibody that competes with the monoclonal antibody CHIR-5.9 or CHIR-12.12 in a competitive binding assay; the monoclonal antibody of preceding item a) or a monoclonal antibody of any one of preceding items c)-i), wherein said antibody is recombinantly produced; and 
monoklonalnog antitijela koje kompetira s monoklonalnim antitijelom CHIR-5.9 koje se dobiva iz hibridomske stanične linije koja je pohranjena kod tvrtke ATCC kao patentna pohrana br. PTA-5542 ili monoklonalno antitijelo CHIR-12.12 koje se dobiva iz hibridomske stanične linije koja je pohranjena kod tvrtke ATCC kao patentna pohrana br. PTA-5543 u testu kompetitivnog vezanja.
The method of claim 48, wherein the pH of the aqueous pharmaceutical formulation is 4.0. The method of claim 48, wherein the aqueous pharmaceutical formulation further comprises at least one excipient selected from the group consisting of zinc, m-cresol, glycerol, and polysorbate 20. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 18, naznačena time što navedeni farmaceutski pripravak dodatno sadrži pomoćne tvari, koje se bira iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
The process of claim 5, wherein the hydrogenation step reduces the amount of 14-hydroxycodeinone in the oxycodone free base or oxycodone HCl. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
The peptide-derived molecule according to claim 8 or the pharmaceutical composition according to claim 8 for use against (i) breast or prostate cancer and/or (ii) another cancer expressing androgen receptors alone or together with estradiol receptors. 
Molekula izvedena iz peptida prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 10 naznačen time da je za upotrebu protiv (i) raka dojke ili prostate i/ili (ii) drugih karcinoma koji eksprimiraju receptore za androgen zasebno ili zajedno s receptorima za estradiol.
A compound according to any one of claims 1 or 3 to 5, wherein R3 represents a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C1-C4 alkoxy group, a C1-C4 haloalkyl group, a C1-C4 hydroxyalkyl group, a C3-C4 cycloalkyl group, a -(CH2)0-3NR'R" group, or a linear or branched C1-C4 alkyl group, which alkyl group is unsubstituted or substituted by a C1-C3 alkoxy group; wherein R' and R" each independently represent a hydrogen atom, a hydroxy group, or a linear or branched C1-C3 alkyl group; 
predstavlja atom vodika, atom halogena, hidroksilnu grupu, cijano grupu, C1-C4 alkoksi grupu, C1-C4 haloalkilnu grupu, C1-C4 hidroksialkilnu grupu, C3-C4 cikloalkilnu grupu, -(CH2)0-3NR'R'' grupu ili linearnu ili razgranatu C1-C4alkilnu grupu, pri čemu je alkilna grupa nesupstituirana ili supstituirana C1-C3 alkoksi grupom; naznačen time, što, R' i R'' svaki zasebno predstavljaju atom vodika, hidroksi grupu ili linearnu ili razgranatu C1-C3 alkilnu grupu;
A CAR according to any one of claims 1 to 3 wherein the spacer comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or a sequence at least 90% identical thereto. 
CAR prema patentnom zahtjevu 9 naznačen time što razmaknica sadrži sekvencu koja je odabrana iz skupine koja se sastoji od SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 ili SEQ ID NO:7 ili a sekvencu koja je njoj najmanje 90% identična.
Competitive Displacement Binding Assays 
Ispitivanja na vezanje uz kompetitivno istiskivanje
Fixed combination, non-fixed combination or kit of parts comprising the compound according to claim 9, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, B2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants and antibiotics, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća spoj prema zahtjevu 9, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti B2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti i antibiotici, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
The compound of claim 3, wherein Ar2 is phenyl, r is 1, 2, 3, 4, or 5, and the Ar2 phenyl is substituted at its 4-position with an R9 group. The compound of claim 5, wherein each R9 group is independently selected from —CF3, —CH2CF3, —Cl, —Br, —OCH3, -iso-propoxy, -tert-butoxy, —OCF3, and —(C1-C6)alkyl. 
Spoj prema zahtjevu 3, naznačen time da Ar, fenil je supstituiran na 4-poziciji. Spoj prema zahtjevu 5, naznačen time da Ar, fenil je supstituiran sa -(C;-Cg) alkilnom skupinom, sa -CF; skupinom, sa -C1, sa -Br, sa -F, sa -I ili sa -OCF;. Spoj prema zahtjevu 6, naznačen time da -(C,-C4) alkilna skupina je fert-butilna skupina ili izo-propilna skupina.
A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein 
1. < Spoj prikazan formulom [I], ili njegova farmaceutski prihvatljiva sol:
7.- The foam spring according to any of the former clauses, wherein the non perforated parts form a plurality of reinfocement ribs equally spaced along the periphery of the tubular body and along its longitudinal axis. 
Pjenasta opruga prema zahtjevu 1, naznačena time što neprobušeni dijelovi (18) formiraju više pojačavajućih rebara (7) koja su jednoliko raspoređena duž ruba cjevastog tijela (2) 1 duž njegove longitudinalne osi (X-X').
The computer program product of claim 7, wherein repairing the invalid field includes disabling the invalid field. 
Produkt računalnog programa prema zahtjevu 5, naznačeno time da popravak (106) nevažećeg polja uključuje onemogućavanje (128) nevažećeg polja.
The turbine of any one of claims 1 to 7 wherein a first resilient element (34) of said at least two elements of differing resilience controls variations in angular disposition of said blades for a first range of wind velocity; a second resilient element (36) of said resilient elements controlling a further variation in said angular disposition of said blades to restrict maximum rotational velocity of said turbine; said first range of wind velocity lying between predetermined values V1 and V2. 
Turbina sukladno bilo kojem od zahtjeva 1 do 7, pri čemu prvi elastični element (34) od najmanje dva navedena elementa različitog elasticiteta upravlja varijacijama kutnog rasporeda navedenih lopatica za prvi raspon od brzine vjetra; drugi elastični element (36) od navedenih elastičnih elemenata upravlja slijedećom varijacijom navedenog kutnog rasporeda navedenih lopatica da bi ograničio maksimalnu brzinu rotacije navedene turbine; navedeni prvi raspon brzine vjetra leži između unaprijed određenih vrijednosti V1 i V2.
The pharmaceutical composition according to claim 1, wherein ropinirole is in the form of ropinirole hydrochloride. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je ropinirol u obliku ropinirol-hidroklorida.
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a temperature that is set at X±0.9°C, wherein X has a value of from 35.1 to 36.5, such as wherein the temperature is set at 36±0.9°C, 36±0.5°C, 36±0.2°C, 36 °C, 35.1±0.9°C, 35.1±0.5°C, 35.1±0.2°C, 35.1°C, 36.5±0.9°C, 36.5±0.5°C, 36.5±0.2°C or 36.5°C, with the proviso that the temperature is set at less than 37°C, wherein the culture is a continuous culture. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X ± 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
The pharmaceutical composition of claim 13 comprising montelukast sodium, hydroxypropylcellulose, sodium starch glycolate, mannitol, color iron oxide, aspartame, flavoring agent, and magnesium stearate. 
Farmaceutska kompozicija prema patentnom zahtjevu 12, naznačena time što sadrži montelukast natrij, laktoza monohidrat, hidroksipropilcelulozu, škrob, natrijev škrob glikolat i magnezijev stearat.
the form includes a first alignment mark in a vicinity of a first edge of the form and a second alignment mark in a vicinity of a second edge of the form; and the processor rotates the form according to the first and second alignment marks. 
Sustav prema patentnom zahtjevu 6, naznačen time, da obrazac uključuje prvu oznaku poravnanja u blizini prvog ruba obrasca i drugu oznaku poravnanja u blizini drugog ruba obrasca; i procesor rotira obrazac u skladu s prvom i drugom oznakom poravnanja.
The process of claim 12, wherein the stainless steel comprises a ferritic stainless steel and the second mixture comprises HNO3. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što nehrđajući čelik sadrži feritni nehrđajući čelik, a druga smjesa sadrži HNO:.
The absorbent sheet (500) according to claim 1, the absorbent sheet (500) further characterized by: 
Metoda za izradu apsorbirajuće celulozne plohe krepirane remenom (10), metoda je karakterizirana:
The method of item 6, comprising combining bupropion, trazodone, and a pharmaceutically acceptable carrier. 
Pripravak koji sadrži trazodon, bupropion, te farmaceutski prihvatljiv nosač za uporabu za liječenje ženske seksualne disfunkcije (FSD).
said pH buffering agent is 10 mM histidine and the pH is 4.5; said bulking agent is 4% w/v mannitol; and said stabilizing agent is 2% w/v sucrose. 
navedeni pH puferski agens je 10 mM histidin i što je pH 4.5; navedeno sredstvo za dopunjavanje je 4% w/v manitol; i navedeni stabilizator je 2% w/v saharoza.
A beverage production system, comprising 
Sustav za pripremanje napitka, koji sustav sadržava
The yarn as claimed in claims 1-9, wherein the textile fibres are Tencel®, cotton, viscose, or comprise lycra or other elastic fibre. The yarn as claimed in claims 1-10, wherein the yarn has a dry tensile strength of at least 10 cN/tex as measured by British Standard ISO 2062 2009. 
kemijsko modificirana pređa da bi se dobila pređa koje se odlikuje stvaranjem gela, pri čemu kemijski modificirana pređa sadrži od 50% do 100% težine vlakana koja stvaraju gel, i ima čvrstoću pri izvlačenju na suho od najmanje 10 cN/tex mjereno prema Britanskom ISO 2062 2009 standardu; I
Use of the droplets according to claim 30 in crop- or plant protection, or fertilisation 
Uporaba postupka prema zahtjevu 29 naznačena time da je za zaštitu za usjeve ili biljke, ili za gnojenje.
A formulation that is reconstituted and diluted can be administered intra-venously using the available protocols. 
Oblik koji je rekonstituiran i razrijeđen može se primjeniti intravenozno primjenom dostupnih protokola.
Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 15, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjela po stanici, ili unos u stanicu antisens oligonukleotida.
Composition according to claim 6 comprising at least one further active ingredient selected from the group of the insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and semiochemicals. 
Pripravak prema zahtjevu 6 naznačen time da sadrži barem jedan daljnji aktivni sastojak koji je odabran iz skupine insekticida, atraktanata, sterilizatora, baktericida, akaricida, nematocida, fungicida, regulatora rasta, herbicida, gnojiva, zaštitnih sredstava i semiokemikalija.
The theoretical maximum number of platelets was calculated. 
Broj objave europskog patenta:
Multilayer films according to claims 1-3 wherein the single packs are cigarette packs arranged one close to the other. 
Primjena u skladu sa patentnim zahtjevima 1-6 gdje pojedinačna pakiranja su pakiranja cigareta raspoređena jedno blizu drugog.
The method of claim 1, wherein the composition comprises a concentration of PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT (SEQ ID NO:4) of 50-500 ug/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 50-500 ug/mL.
The polypeptide of claim 1, comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 residues 1-567. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, koji sadrži aminokiselinsku sekvencu najmanje 95% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1 ili SEK ID BR:35.
A compound for use according to claim 9 or claim 10, wherein the compound of formula (I) is 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine, or a pharmaceutically acceptable salt thereof. 
HR P20100603 T1 ili njegova farmaceutski prihvatljiva sol. Spoj, naznačen time, da je to 4_(trifluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amin, ili njegova farmaceutski prihvatljiva gol,
an engineered targeting antibody against CD138 comprising: 
konstruiranog ciljajućeg protutijela protiv CD1 38, koje sadrži:
FCS= a furin cleavage sequence of 4 to 11 amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end; R2= 1 to 10 amino acid residues; 
FCS = cijepanje sekvencije aminokiselinskih ostataka furinom, koju je sekvenciju moguće cijepati furinom i koja ima na jednom kraju aminokiselinu a na jednom kraju karboksil, pri čemu je taj FCS:
In case of row houses or terraced houses in which the upright building elements are at least partially formed by dividing walls, the walls may be formed in situ or may consist of prefab walls which are erected before the wall elements are placed. 
U slučaju niza kuća ili kuća s terasom kod kojih su uspravni građevni elementi barem djelomično oblikovani pregradnim zidovima, zidovi se mogu oblikovati na mjestu ili se mogu sastojati od unaprijed izrađenih zidova koji se podižu prije nego se postave zidni elementi.
n is 0; is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila, Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj Formule (I) 2-(2-metilpirolidin-2-il)-1H-benzoimidazol-4-karboksamid;
Sleep-wake recording criteria included wakefulness (W), slow wave sleep (SWS) and paradoxical sleep (PS). Spectral analysis of EEG was performed by Fast-Fourier Transform in the 0.8-2.5 Hz, 8-15 Hz and 30-60 Hz frequency bands. 
Kriteriji za bilježenje budnosti-spavanja uključuju budnosti (W, prema engleskom"wakefulness"), san sporih valova (SWS, prema engleskom,,slow wave sleep"), 1 paradoksni san (PS, prema engleskom,,paradoxical sleep").
Tests have shown that the device according to the present invention allows the samples to be taken in a simple and reliable way. 
Ispitivanja su pokazala da naprava koja je u skladu s predmetnim izumom omogućava uzimanje uzorka na jednostavan i pouzdan način.
In a related aspect, the invention provides an isolated nucleic acid molecule encoding an LCVR as described above. 
Ekspresijski vektor, naznačen time, da sadržava molekulu nukleinske kiseline u skladu s patentnim zahtjevom 6.
Anti-Alzheimer's disease active agent for use as in any one of claims 1-7, wherein said treatment is for or comprises delaying the onset of Alzheimer's disease. 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, za uporabu prema bilo kojem zahtjevu od 4 do 7, naznačeno time, da spomenuto liječenje je odgađanje napada Alzheimerove bolesti.
The vaginal semisolid mucoadhesive formulation of claim 5 wherein the fat/lipophilic component is selected from the group consisting of paraffin, petroleum jelly, mineral oil, vegetable oils and hydrogenated vegetable oils. 
Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što masnu odnosno lipofilnu komponentu se bira iz skupine koju čine parafin, vazelin, mineralno ulje, biljna ulja i hidrogenirana biljna ulja.
Method according to Claim 20 where the volume of the tank is at least equal to the volume of the container and in a following step the container is disposed. 
Postupak u skladu s 16, naznačen time što volumen rezervoara je u najmanju ruku jednak volumenu spremnika, a u sljedećem koraku spremnik se baca u smeće.
Preparation of Exemplary Compounds of the Invention 
Datum objave europske prijave patenta:
The composition of claim 1, wherein the carbohydrate is present in an amount sufficient to increase the stability of the GCB. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za povećanje stabilnosti proteina.
agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function); 
(iii) agense koji sprečavaju invaziju tumorskih stanica (na primjer inhibitori metaloproteinaza - marimastat i inhibitore funkcije receptora urokinaznog plazminogenog aktivatora);